Alice Ventures

novoGI™ (previously NiTi Surgical Solutions) is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management. NiTi Surgical Solutions has developed the first major advance in closure for gastrointestinal surgery in more than 30 years. NiTi's proprietary technology represents a breakthrough in natural healing with tissue-sparing, uniform BioDynamix anastomosis. The company's unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling a natural reconnection of the intestine after removing a section, for example, as part of a colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke. Building on its technology, the Company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. In 2008, the company completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011 the Company completed a 300 patients RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.

Tehuti Networks Ltd. (the Company) is a privately held fabless semiconductor company that has developed, a TCP/IP acceleration devices and adapters with the optimal balance of price, performance and power to enable volume adoption of 10 Gigabit Ethernet (GbE). Tehuti's 10GbE controller can operate in a partial offload mode (Stateless) to simplify integration and optimize performance. Founded in 2003, Tehuti Networks is headquartered in Herzliya, Israel. Upon inception, Tehuti was supported by the Technion R&D Fund, an Israeli Government sponsored incubator, to develop and commercialize its TCP/IP acceleration technology. To date, Tehuti Networks has raised venture funds from venture capital firms Alice Ventures, Proseed, Lachman Goldman and TRDF.

Mazor Robotics is a spine surgery innovator—inspiring the art of surgery with guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and OR staff. Renaissance, Mazor Robotics’ new guidance system, is transforming spine surgery from freehand procedures to highly-accurate, state-of-the-art procedures that raise the standard of care with better clinical outcomes. The company was founded by Professor Moshe Shoham and Mr. Eli Zehavi in 2001 and is headquartered in Cesarea, Israel.

Powerlase Photonics Ltd is an innovative, independent, high power laser company, focused on powerful femtosecond, picosecond and nanosecond high energy Diode Pumped Solid State lasers. Powerlase Photonics Ltd has accelerated the introduction of high power lasers into a variety of industrial applications worldwide, primarily in materials processing, marking, annealing, and cleaning as well as other applications. Customer-focused, and with an in-depth knowledge of applications, Powerlase Photonics Ltd enjoys significant expertise in designing and developing state-of-the-art process solutions for flat panel displays, photovoltaic, microelectronics, EUV, machine tool, automotive, and aerospace markets.

Intense Limited designs, manufactures, and supplies single and multimode monolithic laser array products and high power laser diodes. It offers visible laser diode products, such as CW components, modules, and systems; infra-red laser diode products, such as CW components, short pulse components, single mode components, single emitter laser engine, and stacked arrays; laser diode bars and stacked arrays; and individually addressable laser arrays. The company also provides foundry services, including front-end wafer processing, back-end assembly line, engineering support, and product development support services; and laser diode, optics, electronics, and package design services. It serves defense and security, medical, consumer and industrial, foundry services, digital printing and imaging, computer to plate, coding and marking, and display sectors. The company supplies its products through distributors. It has a strategic partnership with IQE. Intense Limited was formerly known as Intense Photonics Limited and changed its name to Intense Limited in March 2005. The company was founded in 1999 and is based in Glasgow, the United Kingdom with manufacturing facilities in the United Kingdom and the United States.

Ignios Ltd., an Oxford, UK-based developer of system-on-a-chip technologies.

Sagitta Ltd. is a technology-based equipment supplier for the fiber optics and semiconductor industries. A core holding of patented technologies in precision automation, machine vision and sub micron polishing has led to the introduction of multiple systems into these markets. The company has introduced the Gemini product series, a platform first in the fiber optics market to integrate the processes of polishing, cleaning and optical metrology on a single platform. Already a leader in failure analysis equipment for the semiconductor and media fields, Sagitta provides an award-winning suite of sample preparation tools used for cross sectional, SEM or TEM semiconductor inspection.

BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke. Building on its technology, the Company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. In 2008, the company completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011 the Company completed a 300 patients RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.

SerCoNet is a developer of Ethernet backbone networking solutions for home consumers & SOHOs (Small Office Home Office) over existing telephone wires.

Arakis Limited is focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy. The company's research capability specializes in the cytokine and receptor mediated mechanisms of disease. The company identifies, develops, and commercializes product opportunities based upon new clinical uses for known drugs or known drug templates, as well as termed performance enhanced medicines.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Arakis Limited is focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy. The company's research capability specializes in the cytokine and receptor mediated mechanisms of disease. The company identifies, develops, and commercializes product opportunities based upon new clinical uses for known drugs or known drug templates, as well as termed performance enhanced medicines.